NASDAQ:DVAX Dynavax Technologies - DVAX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. $11.85 -0.03 (-0.25%) (As of 02/3/2023 11:47 AM ET) Add Compare Share Share Today's Range$11.64▼$11.9250-Day Range$10.27▼$12.7252-Week Range$7.26▼$17.48Volume248,183 shsAverage Volume1.32 million shsMarket Capitalization$1.51 billionP/E Ratio5.72Dividend YieldN/APrice Target$21.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Dynavax Technologies MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside83.8% Upside$21.50 Price TargetShort InterestBearish10.32% of Shares Sold ShortDividend StrengthN/ASustainability-1.59Upright™ Environmental ScoreNews Sentiment1.18Based on 7 Articles This WeekInsider TradingSelling Shares$18.05 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom $1.95 to ($0.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.52 out of 5 starsMedical Sector127th out of 1,029 stocksPharmaceutical Preparations Industry52nd out of 501 stocks 3.5 Analyst's Opinion Consensus RatingDynavax Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.50, Dynavax Technologies has a forecasted upside of 83.8% from its current price of $11.70.Amount of Analyst CoverageDynavax Technologies has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.32% of the outstanding shares of Dynavax Technologies have been sold short.Short Interest Ratio / Days to CoverDynavax Technologies has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Dynavax Technologies has recently increased by 2.89%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDynavax Technologies does not currently pay a dividend.Dividend GrowthDynavax Technologies does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDynavax Technologies has received a 74.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Hepatitis B vaccines", "Clinical research services for infectious diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Dynavax Technologies is -1.59. Previous Next 4.0 News and Social Media Coverage News SentimentDynavax Technologies has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Dynavax Technologies this week, compared to 2 articles on an average week.Search Interest11 people have searched for DVAX on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat Follows5 people have added Dynavax Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dynavax Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,050,984.00 in company stock.Percentage Held by InsidersOnly 9.31% of the stock of Dynavax Technologies is held by insiders.Percentage Held by Institutions94.26% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Dynavax Technologies are expected to decrease in the coming year, from $1.95 to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dynavax Technologies is 5.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.17.Price to Earnings Ratio vs. SectorThe P/E ratio of Dynavax Technologies is 5.65, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 102.75.Price to Book Value per Share RatioDynavax Technologies has a P/B Ratio of 6.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Dynavax Technologies (NASDAQ:DVAX) StockDynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.Read More Receive DVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DVAX Stock News HeadlinesJanuary 31, 2023 | finance.yahoo.comDynavax Announces Uplisting to the Nasdaq Global Select MarketJanuary 28, 2023 | americanbankingnews.comDynavax Technologies (NASDAQ:DVAX) Sees Strong Trading VolumeFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 28, 2023 | americanbankingnews.comDynavax Technologies Co. (NASDAQ:DVAX) to Post FY2023 Earnings of ($0.73) Per Share, William Blair ForecastsJanuary 26, 2023 | finance.yahoo.comWall Street Analysts Think Dynavax Technologies (DVAX) Could Surge 103.22%: Read This Before Placing a BetJanuary 25, 2023 | americanbankingnews.comFY2022 EPS Estimates for Dynavax Technologies Co. (NASDAQ:DVAX) Boosted by William BlairJanuary 16, 2023 | reuters.comDVAX.OQ - | Stock Price & Latest News | ReutersJanuary 15, 2023 | finance.yahoo.comClover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023February 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 9, 2023 | finance.yahoo.comDynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial Highlights and Phase 1 Shingles Topline ResultsJanuary 5, 2023 | thestreet.comDynavax Stock Gaps Down On Today's Open (DVAX)December 18, 2022 | finance.yahoo.comI'm Going to Give This Biotech Another ShotNovember 9, 2022 | finance.yahoo.comDynavax to Present at Two Upcoming Investor ConferencesNovember 9, 2022 | finance.yahoo.comDynavax Technologies Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagNovember 8, 2022 | finance.yahoo.comSurging Earnings Estimates Signal Upside for Dynavax Technologies (DVAX) StockNovember 7, 2022 | finance.yahoo.comDynavax Technologies (DVAX) Recently Broke Out Above the 200-Day Moving AverageNovember 7, 2022 | finance.yahoo.comWall Street Analysts See a 154% Upside in Dynavax Technologies (DVAX): Can the Stock Really Move This High?November 6, 2022 | finance.yahoo.comDowngrade: Here's How Analysts See Dynavax Technologies Corporation (NASDAQ:DVAX) Performing In The Near TermNovember 4, 2022 | seekingalpha.comDynavax Technologies Corporation (DVAX) Q3 2022 Earnings Call TranscriptNovember 4, 2022 | finance.yahoo.comDynavax Technologies (DVAX) Beats Q3 Earnings and Revenue EstimatesNovember 4, 2022 | finance.yahoo.comDynavax Technologies (DVAX) Q3 2022 Earnings Call TranscriptOctober 25, 2022 | finance.yahoo.comDynavax Technologies (DVAX) Recently Broke Out Above the 50-Day Moving AverageOctober 24, 2022 | finance.yahoo.comDynavax Technologies (DVAX) Crossed Above the 20-Day Moving Average: What That Means for InvestorsOctober 21, 2022 | finance.yahoo.comDoes Dynavax Technologies (DVAX) Have the Potential to Rally 210% as Wall Street Analysts Expect?October 21, 2022 | finance.yahoo.comDespite shrinking by US$72m in the past week, Dynavax Technologies (NASDAQ:DVAX) shareholders are still up 116% over 3 yearsOctober 15, 2022 | seekingalpha.comDVAX Dynavax Technologies CorporationOctober 14, 2022 | finance.yahoo.comDynavax to Present at the H.C. Wainwright 3rd Annual Hepatitis B Virus Virtual ConferenceSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address DVAX Company Calendar Last Earnings11/04/2021Today2/03/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:DVAX CUSIP26815810 CIK1029142 Webwww.dynavax.com Phone(510) 848-5100Fax510-848-1327Employees311Year Founded1996Price Target and Rating Average Stock Price Forecast$21.50 High Stock Price Forecast$22.00 Low Stock Price Forecast$21.00 Forecasted Upside/Downside+81.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$2.07 Trailing P/E Ratio5.72 Forward P/E Ratio6.08 P/E GrowthN/ANet Income$76.71 million Net Margins44.35% Pretax Margin44.58% Return on Equity90.54% Return on Assets31.88% Debt Debt-to-Equity Ratio0.44 Current Ratio3.82 Quick Ratio3.40 Sales & Book Value Annual Sales$439.44 million Price / Sales3.44 Cash Flow$1.04 per share Price / Cash Flow11.41 Book Value$1.85 per share Price / Book6.41Miscellaneous Outstanding Shares127,580,000Free Float115,707,000Market Cap$1.51 billion OptionableOptionable Beta1.42 Social Links Key ExecutivesRyan SpencerChief Executive Officer & DirectorDavid F. NovackPresident & Chief Operating OfficerKelly MacDonaldChief Financial Officer & Senior Vice PresidentRobert JanssenChief Medical Officer & SVP-Clinical DevelopmentTodd LopemanVice President-Technical OperationsKey CompetitorsMannKindNASDAQ:MNKDGeronNASDAQ:GERNLigand PharmaceuticalsNASDAQ:LGNDIronwood PharmaceuticalsNASDAQ:IRWDOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsNisa Investment Advisors LLCBought 348,000 shares on 2/2/2023Ownership: 0.276%Monarch Partners Asset Management LLCBought 121,879 shares on 2/2/2023Ownership: 0.096%Simplex Trading LLCSold 31,800 shares on 2/2/2023Ownership: 0.000%Wealth Effects LLCSold 17,500 shares on 2/2/2023Ownership: 0.022%ProShare Advisors LLCBought 2,591 shares on 2/2/2023Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions DVAX Stock - Frequently Asked Questions Should I buy or sell Dynavax Technologies stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DVAX shares. View DVAX analyst ratings or view top-rated stocks. What is Dynavax Technologies' stock price forecast for 2023? 2 Wall Street analysts have issued 1 year target prices for Dynavax Technologies' stock. Their DVAX share price forecasts range from $21.00 to $22.00. On average, they anticipate the company's share price to reach $21.50 in the next twelve months. This suggests a possible upside of 81.0% from the stock's current price. View analysts price targets for DVAX or view top-rated stocks among Wall Street analysts. How have DVAX shares performed in 2023? Dynavax Technologies' stock was trading at $10.64 at the beginning of 2023. Since then, DVAX stock has increased by 11.7% and is now trading at $11.88. View the best growth stocks for 2023 here. When is Dynavax Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our DVAX earnings forecast. How were Dynavax Technologies' earnings last quarter? Dynavax Technologies Co. (NASDAQ:DVAX) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $0.05 by $0.29. The biopharmaceutical company earned $108.27 million during the quarter, compared to analysts' expectations of $77.30 million. Dynavax Technologies had a trailing twelve-month return on equity of 90.54% and a net margin of 44.35%. During the same period last year, the company posted ($0.15) earnings per share. What is Eddie Gray's approval rating as Dynavax Technologies' CEO? 13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend. What other stocks do shareholders of Dynavax Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA). What is Dynavax Technologies' stock symbol? Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX." Who are Dynavax Technologies' major shareholders? Dynavax Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Chicago Capital LLC (4.59%), Nisa Investment Advisors LLC (0.28%), Congress Asset Management Co. MA (0.16%), New York State Teachers Retirement System (0.11%), New York State Common Retirement Fund (0.11%) and Monarch Partners Asset Management LLC (0.10%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer. View institutional ownership trends. How do I buy shares of Dynavax Technologies? Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Dynavax Technologies' stock price today? One share of DVAX stock can currently be purchased for approximately $11.88. How much money does Dynavax Technologies make? Dynavax Technologies (NASDAQ:DVAX) has a market capitalization of $1.52 billion and generates $439.44 million in revenue each year. The biopharmaceutical company earns $76.71 million in net income (profit) each year or $2.07 on an earnings per share basis. How many employees does Dynavax Technologies have? The company employs 311 workers across the globe. How can I contact Dynavax Technologies? Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The official website for the company is www.dynavax.com. The biopharmaceutical company can be reached via phone at (510) 848-5100, via email at ir@dynavax.com, or via fax at 510-848-1327. This page (NASDAQ:DVAX) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.